| 摘要 |
<p num="1"><br/>(see formula 1)<br/><br/><br/><br/>The present invention relates to novel crystalline forms of the platelet <br/>aggregation inhibitor <br/>(+)-(S)-methyl-2-(2-chlorophenyl)-6,7-dihydro-4H-thieno[3,2-c]pyrid-5-<br/>yl)acetate, clopidogrel (1), in the form <br/>of hydrogen bromide salts, identified as polymorph forms 1, 2 and 3. The <br/>present invention further <br/>relates to processes for preparing such forms, pharmaceutical compositions <br/>comprising such forms, <br/>and uses for such forms and compositions. The pharmaceutical compositions may <br/>be used, in <br/>particular, for inhibiting platelet aggregation or for treating, preventing or <br/>managing thrombosis, <br/>atherothrombosis, an atherothrombotic event, ischaemic stroke, myocardial <br/>infarction, non-Q-wave <br/>myocardial infarction, atherosclerosis, peripheral arterial disease, or <br/>unstable angina. The present <br/>invention also relates to methods of treating said disorders.<br/>
|
